Abstracts Archive - Page 1396 of 2607 - ACR Meeting Abstracts

Abstract Number: 130 • 2017 ACR/ARHP Annual Meeting
Availability of Clinical Measures for Patients with Rheumatoid Arthritis in Integrated Delivery Networks Who Receive a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: A Real-World Analysis of an Electronic Health Records Database
Benjamin Chastek¹, Chieh-I Chen², Toshio Kimura², Jonathan Fay², Stephanie Korrer³ and Stefano Fiore⁴, ¹Optum, Eden Prairie, MN, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ⁴Clinical Science, Sanofi Genzyme, Bridgewater, NJ
Background/Purpose: In patients with rheumatoid arthritis (RA), ACR treatment guidelines recommend treating to targets based on quantitative endpoints, with modification of therapy as needed to…
Abstract Number: 131 • 2017 ACR/ARHP Annual Meeting
What Does It Mean to Have Rheumatoid Arthritis Now? a Current Burden of Disease Assessment in the United States
Rebecca Schumacher¹, A Dominique², Sofia Pedro¹, TA Simon² and Kaleb Michaud^1,3, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Known since 1859, RA is the most common inflammatory joint disease with 0.5-1% worldwide prevalence. Currently, there is a larger number of medications and…
Abstract Number: 132 • 2017 ACR/ARHP Annual Meeting
Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients
Pingling Zeng¹, Lars Alfredsson², Lars Klareskog³, Mohammed Mullazehi⁴, Saedis Saevarsdottir⁵, Camilla Bengtsson⁶ and Johan Rönnelid⁷, ¹Institute of Environmental Medicine, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ²The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology,Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁵Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁶Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: We have previously observed an association between exposure to occupational physical workload (PW) and risk of developing rheumatoid arthritis (RA)[1].We posit that PW could…
Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting
Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden
Anders Gülfe¹, Tor Olofsson¹, Jonas K Söderling², Martin Neovius² and Johan K Wallman¹, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…
Abstract Number: 134 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Johan Askling³ and Merete Lund Hetland⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark
Background/Purpose: Hospitalized infections during treatment with biologic disease modifying drugs (bDMARDs) in rheumatoid arthritis (RA) are a concern. This have mainly been studied in patients…
Abstract Number: 135 • 2017 ACR/ARHP Annual Meeting
Comorbidity Measures Differentially Predict Longitudinal Disease Activity, Remission, and Disability in Rheumatoid Arthritis
Bryant R. England¹, Harlan Sayles², Kaleb Michaud², Grant Cannon³, Andreas Reimold⁴, Liron Caplan⁵, Gail S. Kerr⁶, Namrata Singh⁷, Gleb Haynatzki⁸, Michael D. George⁹, Joshua Baker¹⁰ and Ted R. Mikuls¹¹, ¹Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Hospital of Southern Norway, Kristiansand, Norway, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶VAMC, Georgetown University, Washington, DC, ⁷Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ⁸Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Comorbidity frequently complicates rheumatoid arthritis (RA) leading to poor long-term outcomes. However, whether comorbidity influences measures of RA activity over time is less well…
Abstract Number: 136 • 2017 ACR/ARHP Annual Meeting
Prevalence of Rheumatoid Arthritis and Associated Comorbidities in the 2011-2015 Medicare Population
Suying Li, Julia T. Molony, Yi Peng, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting about 1.5 million adults in the US (Helmick et al., 2008). Patients with RA have…
Abstract Number: 137 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and the Risk for Interstitial Lung Disease: A Comparison of Risk Associated with Biologic and Conventional Dmards
Fenglong Xie¹, Narender Annapureddy², Lang Chen¹, Jason Leonard Lobo³, Jim C. Oates⁴, Ankoor Shah⁵, Huifeng Yun⁶, Shuo Yang¹ and Jeffrey R. Curtis⁷, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University Medical Center, Nashville, TN, ³Med-Pulmonary, University of North Carolina, Chapel Hill, NC, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Medicine, Duke University Medical Center, Durham, NC, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interstitial Lung Disease (ILD) is a rare but often severe consequence of several rheumatologic conditions including rheumatoid arthritis (RA). The comparative risk of incident…
Abstract Number: 138 • 2017 ACR/ARHP Annual Meeting
Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity
Fenglong Xie¹, Lang Chen², Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The ACC/AHA recommends preventive strategies for patients with a high predicted risk of atherosclerotic cardiovascular disease (CVD). RA patients are at higher risk for…
Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting
No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016
Seong-Kyu Kim¹, Jung-Yoon Choe², Sung-Hoon Park³ and Hwajeong Lee², ¹Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ²Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ³Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…
Abstract Number: 140 • 2017 ACR/ARHP Annual Meeting
Estimating Prevalence and Cost of Depression Among Japanese RA Patients: A Retrospective Claims Data Base Analysis
Rosarin Sruamsiri¹, Jörg Mahlich² and Yuko Kaneko³, ¹Health Economics, Janssen Pharmaceutical KK,, Tokyo, Japan, ²Health Economics, Janssen Pharmaceutical KK, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Significant evidence in the scholarly literature suggests that depression is a common comorbidity among patients with rheumatoid arthritis (RA) causing significant burden for the…
Abstract Number: 141 • 2017 ACR/ARHP Annual Meeting
Refractory Disease in Rheumatoid Arthritis: Results from the British Society of Rheumatology Biologics Register for Rheumatoid Arthritis
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Kath Watson¹, Maya H. Buch², John D Isaacs³ and Kimme L. Hyrich^1,4, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Biologic therapy has revolutionised treatment pathways and improved outcomes for patients with Rheumatoid Arthritis (RA) who do not tolerate or respond to conventional synthetic…
Abstract Number: 142 • 2017 ACR/ARHP Annual Meeting
Incidence of Hip Fracture in Rheumatoid Arthritis: British Columbia, Canada
C. Allyson Jones¹, Pierre Guy², Hui Xie³, Eric C. Sayre⁴ and Diane Lacaille^5,6, ¹Physical Therapy, University of Alberta, Edmonton, AB, Canada, ²Department of Orthopaedics, University of British Columbia / Centre for Hip Health and Mobility, Vancouver, BC, Canada, ³Biostatistics, Faculty of Health Sciences, Simon Fraser University / Arthritis Research Canada, Burnaby, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada/ University of British Columbia, Vancouver, BC, Canada, ⁶University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Hip fractures have serious long-term effects, including a high 1-year mortality rate (usually 20-30%) and poor functional recovery, with approximately 50% not attaining pre-fracture…
Abstract Number: 143 • 2017 ACR/ARHP Annual Meeting
Patient Rheumatoid Arthritis Data from the Real World (PARADE) Study: Preliminary Results from an Apple Researchkit™ Mobile App-Based Real World Study in the United States
Rachel Williams¹, Emilia Quattrocchi², Sarah Watts³, Sherry Wang⁴, Pam Berry⁴ and Michelle Crouthamel⁴, ¹Real World Evidence and Epidemiology, GSK, Collegeville, PA, ²R&D Immunoinflammation, GSK, Middlesex, United Kingdom, ³GSK, Stevenage, United Kingdom, ⁴GSK, Collegeville, PA
Background/Purpose: Smartphone apps and sensors enable researchers to design novel endpoints and collect real world data directly from patients in a cost-effective, fast, and patient-focused…
Abstract Number: 144 • 2017 ACR/ARHP Annual Meeting
Are RA Patients at a Higher Risk for Car Accidents?
Kaleb Michaud^1,2, Sofia Pedro¹ and Ted R. Mikuls³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an important instrumental activity of daily living with heightened importance among arthritis sufferers who are disproportionately reliant on driving for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].